S/N Unknown

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

John A. Lust et al.

Unknown

Examiner: Unknown Group Art Unit: Unknown

Serial No.: Filed:

June 4, 1999

Docket: 150.188US2

PATEN

Title:

USE OF GENETICALLY ENGINEERED ANTIBODIES TO CD38 TO TREAT

MULTIPLE MYELOMA

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants further request that a copy of the 1449 form, initialled by the Examiner to indicate that all listed citations have been considered, be returned with the next official communication.

Under 37 C.F.R. §1.97(b)(3), it is believed that no fee or certificate is required with this Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

JOHN A. LUST ET AL.

BEST AVAILABLE CO

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6959

Date Derimbers, Jak

Janet E. Embretson Reg. No. 39,665

"Express Mail" mailing label number: EL584209103US Date of Deposit: December 5, 2000

This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to the Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.